This dataset provides detailed records of clinical trial enrollments, including participant demographics, recruitment sources, eligibility criteria, and enrollment status. It enables comprehensive analysis of recruitment flows, diversity metrics, and participant retention, supporting optimization of trial recruitment strategies and regulatory reporting.

Background We examined whether quarterly patient enrollment in a large multicenter clinical trials group could be modeled in terms of predictors including time parameters (such as long-term trends and seasonality), the effect of large trials and the number of new studies launched each quarter. We used the database of all clinical studies launched by the AIDS Clinical Trials Group (ACTG) between October 1986 and November 1999. Analyses were performed in two datasets: one included all studies and substudies (n = 475, total enrollment 69,992 patients) and the other included only main studies (n = 352, total enrollment 57,563 patients). Results Enrollment differed across different months of the year with peaks in spring and late fall. Enrollment accelerated over time (+27 patients per quarter for all studies and +16 patients per quarter for the main studies, p 1,000 (p < 0.001). These relationships remained significant in multivariate autoregressive modeling. A time series based on enrollment during the first 32 quarters could forecast adequately the remaining 21 quarters. Conclusions The fate and popularity of large trials may determine the overall recruitment of multicenter groups. Modeling of enrollment rates may be used to comprehend long-term patterns and to perform future strategic planning.

This survey displays the share of U.S. adults or their family members who participated in a clinical trial by ethnicity, according to a survey conducted in January 2025. Some 20 percent of African-American respondents stated that they or someone from their family ever participated in a clinical trial.

This dataset provides comprehensive information on clinical trial research sites, including site identification, principal investigator details, enrollment statistics, audit and compliance history, and performance metrics. It is designed to support multi-center trial management, site selection, regulatory oversight, and operational optimization for clinical research organizations.

This survey displays the share of U.S. adults or their family members who participated in a clinical trial recommended by their doctor, according to surveys conducted in August 2017, January 2021, and October 2023. Only two percent of respondents in 2023 stated that they would not participate in a clinical trial recommended by their doctor. That was a lower value than in the previous years.

This dataset provides detailed, participant-level records for multiple healthcare clinical trials, including screening, randomization, and enrollment outcomes, along with demographic and site information. It enables comprehensive analysis of trial recruitment, participant flow, and site performance, supporting operational optimization and regulatory reporting in clinical research.

Clinical Trials

Clinical trials over the years along with start / end dates, outcome and more.

By Aero Data Lab [source]

About this dataset

This dataset contains information on clinical trials conducted by sponsors. Each row represents a clinical trial, and the columns represent various attributes of the trial, such as the National Clinical Trial Number, the sponsor of the trial, the title of the trial, and so on.

The purpose of this dataset is to provide a bird's-eye view of the clinical trial landscape. By understanding which sponsors are conducting which trials and for what conditions, we can get a better sense of where research is headed and what new treatments may be on the horizon

How to use the dataset

• NCT is a unique identifier for clinical trials. It stands for National Clinical Trial Number.
• Sponsor is the organization that is funding the clinical trial.
• Title is the name of the clinical trial.
• Summary is a brief summary of the clinical trial.
• Start Year is the year that the clinical trial started.
• Start Month is the month that the clinical trial started.
• Phase is the stage of development of the investigative drug or device (I), which can be one of four types: I, II, III, or IV.
• Enrollment is The number of participants in the clinical trial.
• Status is The status of enrollment in the study, which can be Recruiting, Not yet recruiting, Active, not recruiting, Completed, Suspended, or Terminated.

Condition indicates what medical condition(s) are being studied in this particular NCT record

Research Ideas

• Identify patterns in clinical trials to improve the development process
• Understand how different sponsors fund clinical trials

Acknowledgements

By Aero Data Lab [source]

License

License: Dataset copyright by authors - You are free to: - Share - copy and redistribute the material in any medium or format for any purpose, even commercially. - Adapt - remix, transform, and build upon the material for any purpose, even commercially. - You must: - Give appropriate credit - Provide a link to the license, and indicate if changes were made. - ShareAlike - You must distribute your contributions under the same license as the original. - Keep intact - all notices that refer to this license, including copyright notices.

Columns

File: AERO-BirdsEye-Data.csv | Column name | Description | |:----------------|:-----------------------------------------------------------------| | NCT | National Clinical Trial number. (String) | | Sponsor | Name of the sponsor conducting the clinical trial. (String) | | Title | Title of the clinical trial. (String) | | Summary | Brief summary of the clinical trial. (String) | | Start_Year | Year the clinical trial started. (Integer) | | Start_Month | Month the clinical trial started. (String) | | Phase | Phase of the clinical trial. (String) | | Enrollment | Number of participants enrolled in the clinical trial. (Integer) | | Status | Status of the clinical trial. (String) | | Condition | Condition being tested in the clinical trial. (String) |

Acknowledgements

If you use this dataset in your research, please credit By Aero Data Lab [source]

This survey displays the share of U.S. adults or their family members who participated in a clinical trial according to surveys conducted between August 2017 and January 2025. In the most recent survey, some 15 percent of respondents stated that they or someone from their family ever participated in a clinical trial.

This dataset provides detailed, participant-level tracking of recruitment, eligibility, enrollment, and dropout trends across multiple clinical trials and sites. It enables granular analysis of recruitment strategies, participant demographics, and site performance, supporting optimization of clinical research processes and improved trial outcomes.

The global Clinical Trial Patient Recruitment Services market is experiencing robust growth, driven by the increasing number of clinical trials, rising prevalence of chronic diseases, and the growing demand for faster and more efficient patient enrollment processes. The market size in 2025 is estimated at $2.5 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 12% from 2025 to 2033. This growth is fueled by several key factors. Technological advancements, such as AI-powered patient identification and engagement platforms, are streamlining recruitment processes and reducing timelines. Furthermore, the increasing adoption of decentralized clinical trials (DCTs) is expanding geographical reach and broadening patient pools. The market is segmented by phase (I-IV) and therapeutic area (Respiratory Diseases, Pain and Anesthesia, Oncology, Central Nervous System, Cardiovascular, Endocrine, Anti-Infective, Others), each exhibiting varying growth rates reflecting the specific needs and complexities of each trial type. The North American region currently holds the largest market share, driven by robust research infrastructure and high spending on healthcare. However, emerging markets in Asia Pacific and other regions are showing significant growth potential due to increasing healthcare investments and rising prevalence of target diseases. The competitive landscape is characterized by a mix of large multinational corporations and specialized niche players. Companies like IQVIA, PPD Inc, and Worldwide Clinical Trials dominate the market with their extensive global networks and comprehensive service offerings. However, smaller, agile companies focused on innovative technologies and specialized patient populations are also gaining traction. The market is likely to witness increased consolidation through mergers and acquisitions, as larger players seek to expand their service portfolios and geographic reach. Future growth will be driven by the continuous evolution of recruitment technologies, the growing adoption of real-world data (RWD) for patient identification, and the increasing focus on improving patient experience and trial participation rates. This will lead to greater efficiency, reduced costs, and accelerated drug development processes.

According to a 2019 survey of former clinical trial participants, 21 percent of participants worldwide used text messaging during their clinical trial participation. This statistic depicts the percentage of clinical trial participants that used select technologies during their clinical trial participation as of 2019.

Global clinical trials market was valued at US$ 83.75 Bn in 2024 and is set to reach around US$ 152.84 Bn by 2034 at a CAGR of about 6.2% from 2025 to 2034.

🧪 Covid-19 Clinical Trials Dataset (Raw + Cleaned)

This dataset offers a deep look into the global clinical research landscape during the Covid-19 pandemic. Sourced directly from ClinicalTrials.gov, it provides structured and semi-structured information on registered Covid-19-related clinical trials across countries, sponsors, and phases.

📁 What’s Included • COVID_clinical_trials.csv — Raw dataset as obtained from ClinicalTrials.gov • Covid-19_cleaned_dataset.csv — Preprocessed version for direct use in data analysis and visualization tasks

🎯 Use Case & Learning Goals

This dataset is ideal for: • Practicing data cleaning, preprocessing, and wrangling • Performing exploratory data analysis (EDA) • Building interactive dashboards (e.g., with Tableau or Plotly) • Training ML models for classification or forecasting (e.g., predicting trial outcomes) • Exploring trends in clinical trial research during global health emergencies

🔍 Key Features

Each row represents a registered clinical trial and includes fields such as: • NCT Number (unique ID) • Study Title • Start Date and Completion Date • Phase • Study Type (Interventional/Observational) • Enrollment Size • Country, Sponsor, and Intervention Type • Study Status (Recruiting, Completed, Withdrawn, etc.)

✅ Cleaned Dataset

The cleaned version includes: • Standardized column naming • Filled missing values where possible • Removed duplicates and a few columns

📊 Example Applications • Country-wise contribution analysis • Sponsor landscape visualization • Trial timeline and phase progression charts • Predictive modeling of trial duration or status

🙏 Acknowledgments

Thanks to ClinicalTrials.gov for providing public access to this critical data.

Clinical Trial Patient Recruitment AI Market Outlook

According to our latest research, the global Clinical Trial Patient Recruitment AI market size reached USD 1.18 billion in 2024, reflecting a robust surge in adoption across the clinical research ecosystem. The market is experiencing a remarkable growth trajectory, supported by a CAGR of 20.7% from 2025 to 2033. By the end of 2033, the market is forecasted to reach USD 7.44 billion. This exponential growth is driven by the increasing complexity of clinical trials, rising demand for faster patient enrollment, and the need to reduce trial costs and timelines, as per our latest research findings.

The rapid expansion of the Clinical Trial Patient Recruitment AI market is primarily fueled by the growing complexity and volume of clinical trials globally. Pharmaceutical and biotechnology companies are under immense pressure to accelerate drug development while ensuring regulatory compliance and patient safety. Traditional patient recruitment methods are often inefficient, leading to delays and cost overruns. AI-enabled solutions are transforming this landscape by leveraging advanced data analytics, machine learning, and natural language processing to identify and engage eligible trial participants more effectively. Furthermore, the integration of electronic health records (EHRs) and real-world data sources with AI platforms has significantly enhanced the accuracy and speed of patient matching, thereby improving recruitment outcomes and reducing dropout rates.

Another major growth factor for the Clinical Trial Patient Recruitment AI market is the increasing focus on personalized medicine and rare disease research. As clinical trials become more targeted, the challenge of finding suitable participants intensifies, especially for studies involving rare diseases or highly specific patient subgroups. AI-powered recruitment platforms can analyze vast datasets, including genomic, demographic, and behavioral information, to pinpoint potential candidates who meet stringent inclusion criteria. This capability not only accelerates recruitment but also increases the likelihood of trial success by ensuring a better match between patients and study protocols. Additionally, AI-driven engagement tools, such as chatbots and automated reminders, help maintain patient interest and adherence throughout the trial duration.

The surge in digital health adoption, coupled with growing investments in healthcare AI, is further propelling the market. Governments and private sector stakeholders are increasingly recognizing the value of AI in optimizing clinical research processes. Regulatory agencies are also providing clearer guidance on the use of digital tools and real-world evidence in clinical development, encouraging broader adoption of AI-driven patient recruitment solutions. Moreover, the COVID-19 pandemic has underscored the importance of remote and decentralized trials, accelerating the shift towards cloud-based and virtual recruitment models. These trends collectively contribute to the sustained growth of the Clinical Trial Patient Recruitment AI market worldwide.

AI-Powered Clinical Trial Site Feasibility is revolutionizing the way clinical trials are conducted by optimizing site selection and enhancing trial efficiency. With the increasing complexity of clinical trials, selecting the right sites is crucial for successful patient recruitment and trial execution. AI technologies analyze vast datasets, including historical site performance, demographic data, and geographic factors, to identify the most suitable sites for specific trials. This approach not only streamlines the site selection process but also improves the likelihood of trial success by ensuring that sites have the necessary resources and patient populations. As a result, AI-powered site feasibility assessments are becoming an integral part of clinical trial planning, helping sponsors and CROs make informed decisions and reduce trial timelines.

From a regional standpoint, North America continues to dominate the market, accounting for the largest share in 2024, owing to its advanced healthcare infrastructure, strong presence of leading pharmaceutical companies, and supportive regulatory environment. However, Asia Pacific is emerging as the fastest-growing region, driven by increasing clinical research activities

The Clinical Trial Patient Recruitment Services Market Report is Segmented by Phase (Phase I, and More), Therapeutic Area (Oncology, and More), Service Type (Patient Database & Feasibility Services, and More), Recruitment Channel (Investigator-Site Led, and More), Sponser Type (Medical Device Companies, and More), Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Summary statistics (percentage for categorical variables, median with interquartile range for continuous variables) of features in each enrollment rate categories were shown. “missing” level represents missing value. Only the top 5 most prevalent MeSH terms were shown.

Clinical Trial Patient Recruitment Market Outlook

According to our latest research, the global Clinical Trial Patient Recruitment market size reached USD 4.16 billion in 2024, reflecting a dynamic growth trajectory driven by the increasing complexity and number of clinical trials worldwide. The market is projected to grow at a robust CAGR of 7.2% during the forecast period, reaching an estimated USD 7.72 billion by 2033. This upward momentum is primarily attributed to the rising prevalence of chronic diseases, expanding pharmaceutical pipelines, and the growing adoption of digital recruitment strategies, all of which are reshaping the landscape of clinical research globally.

The growth of the Clinical Trial Patient Recruitment market is profoundly influenced by the escalating demand for innovative therapies and personalized medicine. As pharmaceutical and biotechnology companies intensify their research and development activities, the need to efficiently recruit diverse and representative patient populations has become more critical than ever. The rise in complex clinical trial protocols, particularly in therapeutic areas such as oncology, neurology, and rare diseases, necessitates specialized recruitment services that can navigate regulatory requirements and reach specific patient cohorts. Furthermore, the increasing emphasis on patient-centric approaches and real-world evidence collection is compelling sponsors to invest in advanced recruitment methodologies, thereby fueling market expansion.

Another pivotal growth factor is the integration of digital technologies and data analytics in patient recruitment processes. The adoption of digital channels, including social media campaigns, online patient communities, and AI-driven platforms, has revolutionized the way clinical trials identify, engage, and enroll participants. These technologies enable targeted outreach, enhance patient engagement, and streamline the matching of eligible candidates to appropriate studies. Additionally, the use of electronic health records (EHRs), real-time data mining, and predictive analytics is optimizing site selection and reducing recruitment timelines, which is particularly advantageous in fast-paced therapeutic areas such as infectious diseases and cardiovascular disorders.

Strategic collaborations and partnerships among contract research organizations (CROs), pharmaceutical companies, and patient advocacy groups are also playing a significant role in market growth. By leveraging the expertise of specialized recruitment firms and digital health startups, stakeholders are able to broaden their reach, improve patient retention rates, and ensure compliance with regulatory standards. The increasing globalization of clinical trials, with a notable shift towards emerging markets in Asia Pacific and Latin America, is further expanding the market’s scope. These regions offer access to large, treatment-naive patient populations and favorable regulatory environments, making them attractive destinations for multinational clinical research initiatives.

Regionally, North America continues to dominate the Clinical Trial Patient Recruitment market, accounting for the largest share due to its advanced healthcare infrastructure, high R&D expenditure, and robust regulatory frameworks. However, Asia Pacific is emerging as the fastest-growing region, supported by increasing investments in healthcare, rapid urbanization, and the presence of a vast patient pool. Europe also represents a significant market, driven by stringent clinical trial regulations and a strong focus on innovation. Meanwhile, Latin America and the Middle East & Africa are witnessing steady growth, fueled by improving healthcare access and rising participation in global clinical trials. This regional diversification is expected to further intensify competition and innovation across the market landscape.

Service Type Analysis

The Clinical Trial Patient Recruitment market is segmented by service type into Patient Enrollment, Site Identification, Study Design, Data Management, and Others. Among these, Patient Enrollment remains the cornerstone of the market, accounting for the largest revenue share in 2024. The complexity of enrolling eligible patients, especially in trials involving rare diseases or stringent inclusion criteria, has led sponsors to seek specialized patient enrollment services. These services utilize a combination of traditional outreach, digital mark

This statistic shows the distribution of the top 20 countries worldwide based on clinical trial participants in 2015-2019, by share. In the United States, there were some 35 percent of all clinical trial participants worldwide, which was the largest share amongst all the other countries.

Clinical Trial Recruitment and Management Services Market Outlook

According to our latest research, the global Clinical Trial Recruitment and Management Services market size reached USD 5.7 billion in 2024, reflecting robust demand across healthcare and life sciences sectors. The market is expected to grow at a CAGR of 8.4% from 2025 to 2033, reaching a projected value of USD 11.6 billion by 2033. This growth is primarily driven by the increasing complexity of clinical trials, rising R&D investments by pharmaceutical and biotechnology companies, and the growing prevalence of chronic diseases necessitating new therapeutic solutions.

One of the primary growth factors propelling the Clinical Trial Recruitment and Management Services market is the escalating demand for efficient patient recruitment and retention strategies. As clinical trials become more intricate, with strict eligibility criteria and globalized participant pools, the need for specialized recruitment services has intensified. Companies are leveraging advanced digital tools, artificial intelligence, and patient-centric platforms to streamline the recruitment process, reduce timelines, and improve patient engagement. These technological advancements not only enhance the speed and accuracy of patient identification but also minimize dropout rates, which is vital for the timely completion of trials and regulatory submissions. The integration of big data analytics and real-world evidence further supports the identification of eligible participants, optimizing recruitment outcomes and contributing to overall market expansion.

Another significant driver is the increasing regulatory scrutiny and emphasis on data integrity throughout the clinical trial lifecycle. Regulatory agencies such as the FDA and EMA have heightened their focus on compliance, transparency, and patient safety, compelling sponsors to adopt robust management solutions. This has led to the proliferation of specialized service providers offering end-to-end management, from site selection and monitoring to data management and regulatory compliance. The shift towards decentralized and hybrid clinical trial models, accelerated by the COVID-19 pandemic, has further amplified the need for agile and technology-driven management services. These models enable remote patient monitoring, electronic data capture, and real-time communication, ensuring trials remain on track despite logistical challenges and geographical barriers. As a result, the adoption of comprehensive management services continues to rise, fueling market growth.

The surge in research and development activities, particularly in the fields of oncology, cardiology, and rare diseases, is also a major growth catalyst for the Clinical Trial Recruitment and Management Services market. Pharmaceutical and biotechnology companies are increasingly outsourcing recruitment and management functions to specialized contract research organizations (CROs) to accelerate drug development and bring innovative therapies to market faster. The growing pipeline of drugs in various therapeutic areas, coupled with the need for multicenter and multinational trials, has created a complex operational environment that necessitates expert management. This trend is expected to persist, with emerging markets such as Asia Pacific and Latin America witnessing a surge in clinical trial activity due to favorable regulatory reforms, expanding patient pools, and cost advantages.

Regionally, North America continues to dominate the Clinical Trial Recruitment and Management Services market, accounting for the largest revenue share in 2024. The presence of a well-established pharmaceutical industry, advanced healthcare infrastructure, and a high concentration of clinical trial sites contribute to this leadership. Europe follows closely, supported by harmonized regulatory frameworks and strong government support for clinical research. Meanwhile, the Asia Pacific region is emerging as a key growth engine, driven by increasing R&D investments, expanding patient populations, and rising adoption of digital health technologies. Latin America and the Middle East & Africa are also witnessing gradual growth, fueled by improving healthcare infrastructure and growing participation in global clinical trials.

Clinical trial support service providers have experienced robust growth in recent years, driven by several key factors. Two major catalysts contributing to this growth are an increasing demand for innovative therapies and tech advances. As pharmaceutical companies race to develop new drugs and biologics to address unmet medical needs, the volume and complexity of clinical trials have surged. A jump in clinical trial activity has fueled the need for efficient and reliable solutions to handle challenging aspects of the clinical trial process, including patient recruitment and regulatory compliance. While macroeconomic headwinds have created a complex environment, this is a transient effect and not reflective of broader growth trends in the industry. In all, revenue growth has weakened, falling at a CAGR of 2.0% to an estimated $8.6 billion over the past five years, including expected growth of 2.5% in 2024. A key factor driving the rise of outsourcing in clinical research is the increasingly complex landscape of clinical trials. Advances in medicine and technology have made the trial process more intricate, leading to a greater volume and diversity of tasks, from patient recruitment to regulatory compliance. These complexities pose significant challenges that pharmaceutical and biotechnology companies are addressing through clinical trial support services. Outsourcing these services has become particularly important for smaller pharmaceutical companies that rely on successful clinical trials but lack the capital or infrastructure to manage all aspects in-house. By leveraging outsourced expertise, these companies can focus on their core activities while ensuring trials are conducted smoothly and effectively. Outsourcing components of the research and development phase is becoming an appealing strategy for downstream pharmaceutical and medical device manufacturers, setting the stage for the industry’s growth. Smaller and mid-sized pharmaceutical firms will vie with major multinational companies to introduce innovative therapies, strengthening the industry’s role. Additionally, a looming patent cliff will spur demand for outsourced clinical trial services as revenue drops and heightened competition from generic drugs prompt these manufacturers to boost clinical trial activities and implement cost-saving measures. Revenue will continue growing, rising at a CAGR of 3.1% over the next five years, reaching an estimated $9.9 billion in 2029.